Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MST1R | Q04912 | 1/20 | 0.40 |
| ▸ | INPPL1 | O15357 | 7/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581742 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL2419732 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL488680 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30005568 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30005904 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30509670 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30765076 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 | |
| SCHEMBL1582536 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 | |
| SCHEMBL488432 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 | |
| SCHEMBL28018826 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082110-B | The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2024-04-12 | — | — | CN | claimed |
| CN-116082110-A | The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2023-05-09 | — | — | CN | claimed |
| CN-116496140-B | Preparation method of tenidine drug intermediate | 凯特立斯（深圳）科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-114105962-B | Sulfonamide structure-containing compound, preparation method and application thereof, pharmaceutical composition and application thereof | 南京烁慧医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-116082110-B | The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2024-04-12 | — | — | CN | disclosed |
| CN-116496140-A | Preparation method of tenidine drug intermediate | 凯特立斯（深圳）科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115448813-B | Method for preparing (S) -2, 6-dichloro-3-fluorophenylethanol | 中国科学院兰州化学物理研究所 | 2023-07-25 | — | — | CN | disclosed |
| CN-116082110-A | The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2023-05-09 | — | — | CN | disclosed |
| CN-112010860-B | Benzyloxypyrazolopyrimidine compounds, pharmaceutical compositions and uses thereof | 南京纳丁菲医药科技有限公司 | 2023-03-10 | — | — | CN | disclosed |